Neil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.
Neil Vasan, MD, PhD
Advertisement
Articles by Neil Vasan, MD, PhD
Neil Vasan, MD, PhD, discusses how the results of the TRAIN-2 trial impacted the treatment of patients with HER2-positive breast cancer.
Advertisement
Latest Updated Articles
TRAIN-2 Trial Leads to Changes in Treatment of HER2+ Breast CancerPublished: June 12th 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
